FLX-925

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameFLX-925
Drug Alias NameAMG-925FLX-925
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsCyclin-dependent kinase 6Tyrosine-protein kinase receptor FLT3Cyclin-dependent kinase 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRapt Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A